Today: 27 November 2025
Subscribe
Browse Category

Healthcare Industry News 11 November 2025 - 26 November 2025

Abbott Laboratories (ABT) Stock Today, November 26, 2025: Insider Sale, $21B Exact Sciences Deal and Libre 3 Sensor Correction in Focus

Abbott Laboratories (ABT) Stock Today, November 26, 2025: Insider Sale, $21B Exact Sciences Deal and Libre 3 Sensor Correction in Focus

Abbott Laboratories (NYSE: ABT) enters Wednesday, November 26, 2025 with its share price hovering around $128 after a modest gain in Tuesday’s session. Investors are weighing three main storylines: a fresh insider stock sale, the $21 billion takeover of Exact
26 November 2025
 ·  ·  ·  ·  · 
Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna (MRNA) secured a $1.5 billion Ares loan, outlined a three‑year strategy targeting up to 10% revenue growth in 2026, and confirmed a $140 million U.S. manufacturing expansion as it races toward cash breakeven by 2028. Moderna’s pivotal day: liquidity
20 November 2025
 ·  ·  ·  ·  · 
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Stock Today (November 20, 2025): Wegovy Price Cuts, Alzheimer’s ‘Lottery Ticket’ Trials and Denmark GDP Put NVO Back in the Spotlight

Novo Nordisk stock is back on traders’ screens today as a cluster of fresh headlines – from high‑stakes Alzheimer’s trials to aggressive Wegovy price cuts and new Danish GDP data – reshapes the narrative around the Ozempic maker. On Thursday,
20 November 2025
 ·  ·  ·  ·  · 
Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer’s acquisition of Metsera, Inc. (formerly NASDAQ: MTSR) is now effectively complete, Metsera’s stock has been delisted, major index providers are removing the name, and antitrust scholars are using the failed Novo Nordisk bid as a case study in “attempted
17 November 2025
 ·  ·  ·  ·  ·  · 
UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

UNH Stock Forecast for 2026: Can UnitedHealth Survive the DOJ Storm and Medicare Cuts? (Updated November 15, 2025)

UnitedHealth Group’s UNH stock has become one of the most controversial names in the Dow in 2025. After a brutal sell-off driven by a massive cyberattack, rising medical costs and intensifying federal investigations, the stock is trying to stage a
15 November 2025
 ·  ·  ·  ·  · 
Pfizer Completes $10 Billion Metsera (MTSR) Buyout as Nasdaq Delists Stock Today

Pfizer Completes $10 Billion Metsera (MTSR) Buyout as Nasdaq Delists Stock Today

Metsera Inc. (NASDAQ: MTSR) stops trading today, November 14, 2025, as Pfizer closes its up to $10 billion obesity-drug acquisition. Here’s what Metsera shareholders and obesity-market investors need to know about the deal terms, CVR, delisting, and future milestones. Date:
14 November 2025
 ·  ·  ·  ·  ·  · 
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk (NVO) Today — Nov. 12, 2025: WeightWatchers to Offer Wegovy Pill, Canada Eyes Ozempic Copies, and the Latest Stock Move

Published: November 12, 2025 Summary: WeightWatchers says it will sell Wegovy in a pill once launched WeightWatchers (WW) plans to carry Novo Nordisk’s oral Wegovy, pending U.S. approval, leaning into consumer preference for pills over injections and differentiating from rivals
12 November 2025
 ·  ·  ·  ·  · 
1 2 3
Go toTop